Hire an Advanced Robo-Advisor to Trade LLY on Your Behalf.
- Street Sentiment
- Personalized Strategy
- Free Trading Simulator
Course of Action
Sentiment (10 days)
- Strong Buy
- Strong Sell
DAILY PRICE CHANGE VS SENTIMENT
Why Smart Auto-Trading?
Smart Auto-Trading is an advanced Robo-Trader designed to automate systematic stock investing. Its robo is designed to screens, monitors and auto-trades elite stocks like ELI LILLY AND COMPANY (LLY) using Artificial Intelligence signals. It is designed to augment your profit potential.
Smart Auto-Trading produces short-term trades which makes it an ideal tool for trading in tax-deferred accounts such as IRA, SIMPLE IRA, Rollover IRA, 529 College Plans, Keoghs and UGMAs. If also works in taxable accounts. Just be aware that if you elect to auto-trade using Smart Auto-Trading in a regular brokerage account, you will be taxed at regular income. Make sure you understand your tax situation before using Smart Auto-trading.
Using Smart Auto-Trading is easy. It connects to your brokerage account at Ally Invest. Ally Invest is one of the most trusted broker/dealer in the United States. All you need to do is open an account with them, put a minimum of $25,000 in your account and connect Smart Auto-Trading to auto-trade.
There are clear benefits associated with using a robo-Trader such as Smart Auto-Trading to help you reach your financial goals. Smart Auto-Trading simplifies stock investing down to a few steps. It auto-trades for you, using your personalized strategy, while you attend more important life events.
Using Smart Auto-Trading is like having thousands of traders working for you to help you reach your financial goals.
Smart Auto-Trading actively trades the S&P 500 on your behalf. Its Artificial Intelligence is on the lookout, working to maximize your potential every business day of the year. It 'trades on the news' taking advantage of price changes and trends by listening to trader's communications and by validating this information with market data.
Smart Auto-Trading is one of the first robo-Trader to take advantage of Government grade listening technology, Artificial Intelligence, social media and market data natively.
Try Smart Auto-Trading today!
You can test Smart Auto-Trading in simulation mode, risk free, Stock Circles today.
Disclaimer: Past performance may not be indicative of future results. Therefore, you should assume that the future performance of any specific investment, investment strategy (including robo-strategies), or product made in reference directly or indirectly on this website, will be profitable or equal to corresponding indicated performance levels. Robot-Traders like other investment methods rely on favorable market conditions to provide positive outcomes.
ELI LILLY AND COMPANY (LLY) News
Sue Mahony to Retire as President of Lilly Oncology
Eli Lilly and Company (NYSE: LLY) announced today that Sue Mahony, Ph.D., senior vice president of Lilly and president of Lilly Oncology, will retire at the end of August after 18 years of service with the company. Mahony is also a member of Lilly's executive committee.
"On behalf of our executive team and the company, I want to thank Sue for her leadership over the past 18 years," said David A. Ricks, Lilly's chairman and chief executive officer. "Her passion for patients and strong sense of purpose are inspiring to all of us."
Mahony led Lilly Oncology through the integration of ImClone, successfully launched several key brands—including Verzenio™—and most recently led the refocusing of the company's oncology R&D strategy. Prior to this, as senior vice president of human resources and diversity, Mahony played a key role in restructuring the company into business units.
Mahony joined Lilly in 2000 after more than a decade in sales and marketing roles in Europe for Schering-Plough, Amgen and Bristol-Myers Squibb. At Lilly, Mahony has held senior leadership positions in product development, Six Sigma, marketing and general management roles.
"What I've appreciated over the years is the opportunity to participate in something greater than myself," said Mahony. "We make medicines that help patients with cancer live longer. What a privilege it's been to wake up each morning with that as my life's work."
Lilly is considering internal and external candidates to succeed Mahony.Get Started today! - Risk Free